Supervisory Board

Biography 

Prof. Dr Iris Löw-Friedrich (born in 1960, German citizen) was appointed Member of the Supervisory Board on 17 June 2014 and was re-elected as Member of the Supervisory Board by the Annual General Meeting 2019 on 19 June 2019 for a term of five years. Since 15 June 2021 she has been serving as chairwoman of the Supervisory Board. Her current term will expire at the end of the Annual General Meeting held in the year 2026.

From 2008 to 2024, Prof. Dr Iris Löw-Friedrich served as Chief Medical Officer and Executive Vice President Development and Medical Practices of UCB S.A., Brussels (Belgium).

From 2001 to 2009, Prof. Dr Löw-Friedrich was a member of the Executive Board of Schwarz Pharma AG, Monheim am Rhein, with global responsibility for research and development. From 2000 to 2001, she served as Vice President Global Projects at BASF Pharma, Ludwigshafen.

From 1992 to 2000, Prof. Dr Löw-Friedrich held various positions in the area of drug development at Hoechst AG, Frankfurt am Main, lastly as Vice President Clinical Development at Hoechst Marion Roussel/Aventis, Bridgewater, NJ, USA.

Since April 2014, she has been Member of the Board of Directors at TransCelerate BioPharma Inc (Chairman of the Board of Directors from September 2015 until September 2017). TransCelerate BioPharma Inc is a non-profit organisation with membership of 20 major life science companies, including UCB. Since April 2019, she is also a member of the Board of Directors of PhRMA Foundation in Washington DC (US).

Since May 2016, Prof. Dr Löw-Friedrich has been serving as Member of the Supervisory Board of Fresenius SE & Co. KGaA. Prof. Dr Löw-Friedrich began her career in 1985 as a physician in the field of internal medicine at the University of Frankfurt/Main, Medical School, where she has also been a clinical professor for internal medicine since 2000. Since November 2024, she is also Chair of the Supervisory Board of Celosia Therapeutics Pty Ltd. (New South Wales, Australia).

Prof. Dr Löw-Friedrich began her career in 1985 as a physician in the field of internal medicine at the University of Frankfurt/Main, Medical School, where she has also been a clinical professor for internal medicine since 2000.

She studied medicine at the University of Frankfurt/Main, receiving her doctorate from this university in 1985.

Prof Dr Iris Löw-Friedrich is independent in the opinion of the Company. Her position on the Executive Board of UCB S.A., which has a business relationship with Evotec SE, does not constitute dependency. Business relationships constitute a material and prolonged conflict of interest only in exceptional cases. The Supervisory Board has no influence on the volume of orders or the continuation or expansion of business relationships. This is the responsibility of the Management Board of Evotec SE, which not only represents the Company (section 78 of the German Stock Corporation Act (AktG)), but also makes decisions on these matters under its own responsibility (section 76, paragraph 1 of the German Stock Corporation Act (AktG)). There is also no intersecting executive body position.

Biography 

Mr Roland Sackers (born in 1968, German citizen) was appointed Member of the Supervisory Board on 19 June 2019 for a term of five years. Since 15 June 2021 he is Vice Chairman of the Supervisory Board. His current term will expire at the end of the Annual General Meeting held in the year 2027.

Mr Sackers has been serving as Chief Financial Officer of QIAGEN N.V. since January 2004. In this position, he is responsible for developing and executing the long-term financial planning, which is the foundation for the company’s accelerated growth strategy.

Prior to joining QIAGEN in 1999, Mr Sackers served as Auditor at the auditing company Arthur Andersen.

Mr Sackers received his master’s degree in Business Administration from the University of Münster.

He represents QIAGEN as board member of BIO Deutschland e.V. Mr Roland Sackers (CFO of Qiagen N.V.) is independent. Qiagen N.V. has no significant business relationship with Evotec SE, and no other circumstances leading to dependency are apparent.

Biography 

Mrs Camilla Macapili Languille (born 1983, Canadian citizen) was appointed Member of the Supervisory Board on 22 June 2022. Her current term will expire at the end of the Annual General Meeting held in the year 2027.

Camilla Macapili Languille is Deputy CEO of Mubadala’s Direct Investments platform, which executes global direct investments with a focus on private equity and actively manages a portfolio targeting growth-oriented companies across a range of sectors, including Healthcare, Consumer, Financial Services, Industrial & Business Services, Energy & Sustainability, and Globalfoundries (semiconductors).

Camilla has been with Mubadala Direct Investments since 2013 and has led the buildout of its global Healthcare portfolio and investments team. As the former Head of Healthcare, Camilla was responsible for executing investments in companies such as PCI Pharma, Envirotainer, Evotec, and Norstella, amongst others, and for building a ~25-person global investments team across Abu Dhabi, New York, London, and Beijing. Prior to launching the Healthcare business, Camilla was responsible for managing the Semiconductors portfolio, including Globalfoundries and Advanced Micro Devices (AMD). She started her journey in Mubadala overseeing the Utilities and Mining portfolios.

Prior to joining Mubadala, Camilla previously worked in M&A for Daiwa Capital and Société Générale based in Paris, as well as in private equity and growth equity investments for Virgin Group in London, where she managed the Special Situations portfolio and supported the launch of Virgin Healthcare. She began her career in Healthcare M&A for JPMorgan in New York and London.

Camilla currently serves on the Boards of Globalfoundries Inc and PCI Pharma. She also serves as the Co-Chair of Mubadala’s Direct Investments Investment Committee and as a member of Mubadala’s Group Investment Committee.

Camilla holds a Bachelor’s degree in Economics & Political Science from Columbia University (summa cum laude). She is a Canadian by nationality, has lived in 14 countries, and is fluent in English and French.

Biography

Dr Ulmer-Eilfort (born in 1962, German citizen) has more than twenty years’ experience in advising high-tech, pharmaceutical and media companies on the protection and marketing of their intellectual property rights. As a Partner with PSP München, she advises on a wide range of agreements, including cooperation and licensing agreements, R&D agreements and agreements with academic institutions.

Previously, Dr Ulmer-Eilfort was a Partner with the international law firm Baker McKenzie where she was also a member of the Global Executive, chairing the Global Financial Committee and overseeing the budgeting process and budget controls worldwide.

Dr Ulmer-Eilfort’s leadership roles in both management and supervisory functions as well as her specialisation in the protection and marketing of intellectual property and corporate governance are an ideal qualification for her membership of the Supervisory Board of Evotec SE.

Dr Ulmer-Eilfort is to be considered as independent as she has no business relationship with Evotec SE and no other circumstances leading to dependency are apparent. She is member of the advisory board of Proxygen GmbH. Furthermore, Dr Ulmer-Eilforth serves as member of the Supervisory Board of Affimed NV. 

Biography

Dr Duncan McHale (born 1966, British citizen) is the Founder and Company Director of Weatherden Ltd, based in London, UK, a position he has held since 2017. Prior to this, Duncan served as the Chief Medical Officer at Evelo Biosciences from 2017 to 2023. From 2011 to 2017, he was the Vice President and Head of Global Exploratory Development at UCB. Between 2008 and 2011, he held various positions at AstraZeneca, culminating in the role of Vice President of Personalized Healthcare and Biomarkers. His career also includes several roles at Pfizer from 1999 to 2007, with his most recent position being Executive Director, European Head of Molecular Profiling and TA lead for Pain, Sex Health, and Urology at Pfizer Global Research and Development's Sandwich Laboratories.

Duncan holds a Doctor of Philosophy (“PhD”) in Human/Medical Genetics from the University of Leeds, and earned his Bachelor of Medicine, Bachelor of Surgery from the University of Newcastle-Upon-Tyne. He has been awarded Membership of the Royal College of Physicians (“MRCP”). Additionally, he was awarded Membership of the Faculty of Pharmaceutical Medicine by distinction, which is the qualification for pharmaceutical physicians in the UK. Duncan retains his medical license to practice.

Biography

Wes Wheeler is a 43 year operations executive starting as a project engineer with Exxon Research & Engineering (now ExxonMobil), but for the past 34 years has held many diverse leadership positions in the pharmaceutical industry. He moved from Exxon to GlaxoSmithKline and worked for 13 years in engineering, marketing and spent his final five years as senior Vice President of Global Manufacturing & Supply. During these final years at GSK, Wes was responsible for transforming the global network of manufacturing sites and managed the merger of GlaxoWellcome and SmithKline Beecham manufacturing operations. He then moved to CEO of DSM Pharmaceuticals, a Division of DSM in the Netherlands, where he was hired to navigate the company through an FDA Warning Letter and turn the company around, which he did in 15 months. After leaving DSM, Wes became President of Valeant Pharmaceuticals International (now Bausch Health) and was responsible for the North American business, global marketing, M&A and the research & development division. Following Valeant, Wes became CEO of Patheon (now a ThermoFisher company), a public company traded on the Toronto Stock Exchange. Patheon was a turnaround opportunity which became the No. 2 contract manufacturing in the industry and at the same time endured a hostile take-private ownership change by JLL Partners. Wes then accepted a role as CEO of Marken, a leading privately held clinical trials logistics company. The Marken turnaround was five years in the making, resulting in the sale of the company to UPS in 2016. Marken is now a billion-dollar company and a global leader in the clinical trials services industry. In his final three years at UPS, Wes was named President of UPS Healthcare, the first vertical business unit ever created at UPS which he grew from $6 to $10 billion in revenue. He was the first private industry leader named to ‘Operation Warp Speed’, the US presidential task force which managing the response to the pandemic. During this time, his new UPS division managed the storage and distribution of nearly 2 billion doses of the COVID-19 vaccine to over 100 countries.

Wes holds a Bachelor’s Degree in Mechanical Engineering and a Masters of Business Administration. He was Director and Chairman of Bushu Pharmaceuticals which was sold to KKR in 2022, He is currently Executive Chairman of BioTouch International and a Board Director with Envirotainer, an EQT company.